Platform
Products
- Digistain Breast
Partners
Investors
About
- About Digistain
- Team
News
Contact

✕

Platform
Products
- Digistain Breast
Partners
Investors
About
- About Digistain
- Team
News
Contact

NHS Oxford’s UK Access Program

Home
News
News
NHS Oxford’s UK Access Program

2023 FINALIST LOGOS Advances Digital Healthcar

Medilink Business Awards 2023

January 28, 2023

WhatsApp Image 2023 04 29 at 21.15.31

Digistain at the American Society of Breast Surgeons Annual Symposium 2023

2023 FINALIST LOGOS Advances Digital Healthcar

Medilink Business Awards 2023

January 28, 2023

WhatsApp Image 2023 04 29 at 21.15.31

Digistain at the American Society of Breast Surgeons Annual Symposium 2023

March 1, 2023

Categories

News

Tags

thehill

Honoured today to be offered a place on NHS Oxford’s UK Access Program! #digitalhealth #accelerator

Share

Related posts

November 3, 2026

Digistain nominated for the EIT Awards 2026

November 3, 2026

Digistain at On Targeted Molecular Oncology 2026, Ankara

November 3, 2026

The Future Health Dialogue, Abu Dhabi

Comments are closed.

Digistain is a cancer biomarker company. Its breast cancer recurrence-risk test measures the tumour’s biochemistry directly, with results before the next appointment.

LRQA certified ISO 13485

Platform

Overview
How it works
Research and pipeline
Publications

Digistain Breast

Overview
For clinicians
For laboratories
For patients

Company

Partners
Investors
About
Team
News
Contact

© 2026 Digistain Ltd · ISO 13485:2016 certified (LRQA) for the design and development of IVD software used in cancer management · Privacy policy · Terms and conditions · Cookie policy